Neonatal phototherapy: choice of device and outcome

V. Bhutani,R. Wong

DOI: https://doi.org/10.1111/j.1651-2227.2012.02605.x

2012-05-01

Acta Paediatrica

Abstract:Over the past five decades, phototherapy has become a bastion of neonatal practice although it was met initially with scepticism. Through its wide clinical application in developed nations, phototherapy not only effectively reduces bilirubin levels and the need for exchange transfusions; but also, has reduced the occurrence of kernicterus as well as having a possible role in reversing early acute bilirubin encephalopathy (ABE) when used in a ‘crash-cart mode’ (1,2). However, ensuing commercial and indigenous device adaptations of current (or available devices) have often been performed without rigour of scientific inquiry as to the safety, efficacy and actual performance of these devices prior to their clinical use. In 1998, Vreman et al. (3) pioneered the use of unique semiconductor light-emitting diodes (LEDs) that emitted blue light within a narrow bandwidth as a light source for neonatal phototherapy, which not only may provide higher irradiance levels, but also lead to the development and design of direct contact phototherapy with a mattress-like device that has minimal heat production, is portable, has limited glass parts and is energy-efficient (4,5). Now, two systematic reviews of four randomized controlled trials show comparable rates of declines in total serum bilirubin (TSB) levels and in the duration of phototherapy using current LED-based devices versus other light sources (6,7). The theory that a phototherapy light source should be designed to emit light at the wavelength that matches the specific peak bilirubin absorption was the goal of Cremer et al. (8) and Perryman et al. (9) when they first developed the phototherapy device. Since then, the choice of light sources has been primarily dependent on the manufacturer with occasional input from expert photobiologists, but has been limited by the manufacturer’s ability to provide ‘optimal’ wavelength light, varying irradiance and maximal and uniform light exposure to an infant’s body surface area (2). These ‘newer’ devices expose the limited evidentiary basis for our current use of the commercially available phototherapy devices. Use of light as a potential ‘drug’ needs to be a ‘prescriptive approach’ that is based on the dose of light given, adjusted for the exposed body surface area with a predictable and consistent response, and prescribed for specific indications. Indications for use are distinct: (i) prevention and treatment of progressive ABE or (ii) reduction of bilirubin load. The inherent biological variability of infants with severe hyperbilirubinaemia is known to be dependent of the dynamic rates of bilirubin production and bilirubin elimination with resultant changes of the hour-specific bilirubin value often described by the Valaes Equation (10). Vulnerability to bilirubin neurotoxicity is also associated with gestational age, postnatal age, concurrent haemolysis and rate of bilirubin–albumin binding (1). Unmeasured clinical factors include the refraction of light below the skin surface, confounding effects of other pigments such as melanin, Invited Commentary for Ascanio Tridente et al. Efficacy of Light Emitting Diode versus other Light Sources for Treatment of Neonatal Hyperbilirubinemia: a Systematic Review and Meta-Analysis, pages 458–465.